Background Cholangiocarcinoma is frequently observed in patients with congenital bile duct dilatation (CBDD). Most cholangiocarcinomas are adenocarcinomas. Other types, especially neuroendocrine carcinomas (NECs), are rare. To the best of our knowledge, this is the third reported case of an NEC of the common bile duct associated with CBDD and the first to receive adjuvant chemotherapy for advanced disease. Case presentation A 29-year-old woman presented with upper abdominal pain. Preoperative imaging indicated marked dilatation of the common bile duct and a tumor in the middle portion of the common bile duct. She was suspected of having distal cholangiocarcinoma associated with CBDD and underwent pylorus-preserving pancreaticoduodenectomy. Pathological and immunohistological findings led to a final diagnosis of large-cell NEC (pT3aN1M0 pStageIIB). The postoperative course was uneventful, and she was administered cisplatin and irinotecan every 4 weeks (four cycles) as adjuvant chemotherapy. She has remained recurrence-free for 16 months. Conclusions NEC might be a differential diagnosis in cases of cholangial tumor associated with congenital bile duct dilatation. This presentation is rare and valuable, and to establish better treatment for NEC, further reports are necessary.
1 January 2025 in Asian Journal of Endoscopic Surgery
Introduction: Minimally invasive surgery for congenital biliary dilatation (MICBD), including both laparoscopic and robotic approaches, is gaining increasing popularity. However, the evidence remains limited, especially across both adult and pediatric populations. Methods: Consensus statements on MICBD were formulated during a multidisciplinary consensus meeting, addressing two clinical questions focused on the use of MICBD in Todani classification types I and IV‐A. A comprehensive literature review and expert survey were performed. Consensus was achieved through a Delphi voting process, with statements approved when ≥ 75% agreement was reached. Results: The literature review revealed that although MICBD was associated with prolonged operative times, the approach resulted in reduced blood loss and shorter hospital stays, with complication rates comparable to those observed in open surgery. In the expert survey, MICBD was supported by 81% of respondents for type I and 64% for type IV‐A. The following consensus statement was developed: “MICBD for both Todani classification type I and type IV‐A can be considered; however, it is preferable for the procedure to be performed by a team experience in minimally invasive surgery.” This statement achieved unanimous agreement in the Delphi vote. Conclusion: Due to a lack of high‐level evidence, formal recommendations for MICBD remain premature. Expert consensus supports MICBD for both types I and IV‐A cases, provided that the procedures are performed by experienced surgical teams. Further high‐quality studies and long‐term outcome assessments are essential to establish safety and efficacy.
1 January 2025 in Asian Journal of Endoscopic Surgery
Background: Resection of the extrahepatic bile duct including the gallbladder and the dilated segment, is a widely accepted surgical concept in congenital biliary dilatation (CBD) in both adult and pediatric surgeons. However, owing to the existence of various types of CBD and differences in the extent of dilatation, no consensus has been reached regarding the appropriate resection margins. Methods: Consensus statements regarding the appropriate surgical margins for both the duodenal and hepatic hilum sides were developed as two clinical questions (CQs) during a multidisciplinary consensus meeting. A comprehensive literature review and expert survey were conducted. Consensus was achieved through a Delphi voting process, with statements approved when ≥ 75% agreement was reached. Results: In a nationwide expert survey, pediatric institutions resected the bile duct closer to the junction of the pancreatic duct on the duodenal side relative to adult institutions. In contrast, adult institutions aggressively transected higher levels of the hepatic duct on the hilum side. Taking literature reviews into account, the following consensus statement was developed: “The narrow segment is a good landmark to remove closely to the pancreatic junction on the duodenal side and the decision on the resection line on the hepatic hilum side should be dependent on the type of Todani's classification.” This statement achieved a unanimous agreement in the Delphi vote. Conclusion: It should be noted that there are differences in surgical concepts between adult and pediatric institutions. Further research is needed to determine the long‐term outcomes related to the resection line.
11 January 2026 in Asian Journal of Endoscopic Surgery
Introduction: With the aim of facilitating cross‐specialty discussion on detailed anatomical interpretations in congenital biliary dilatation surgery, the Japan Society for Endoscopic Surgery (JSES) and the Consensus Meeting of Anatomy on the Border (AOB) developed a series of consensus statements in 2024. This report focuses specifically on biliary reconstruction for intrahepatic bile duct strictures and the optimal jejunal limb length. Methods: These statements were based on a comprehensive literature review and a nationwide questionnaire survey. Results: For intrahepatic bile duct strictures, the need to tailor surgical approaches according to the location and underlying cause of the stricture has been recognized. When a stricture was located in the hilar or proximal intrahepatic bile ducts and direct surgical intervention was feasible, procedures such as stricture repair, membranous resection, or septal excision were commonly performed. In contrast, when the stricture was located more peripherally and direct intervention was difficult, alternative strategies, such as hepatectomy, endoscopic bile duct reconstruction, or additional hepaticojejunostomy to the upstream bile duct, were employed. For the optimal length of the jejunal limb, it is recommended that the jejunal limb length be adjusted according to body size in children under 5 years of age, and that the natural length be applied in children 5 years of age and older, as well as in adults. Conclusion: The current evidence remains insufficient and further research is warranted to establish more definitive conclusions. This statement was finalized with the agreement of all expert panel members.
Background Cholangiocarcinoma is frequently seen in patients with congenital bile duct dilatation (CBD). Most cholangiocarcinomas are adenocarcinomas. Other types, especially neuroendocrine carcinomas (NECs), are rare. To the best of our knowledge, this is the third reported case of an NEC of the common bile duct associated with CBD and the first to receive adjuvant chemotherapy for advanced disease. Case presentation A 29-year-old woman presented with upper abdominal pain. Preoperative imaging indicated marked dilatation of the common bile duct and a tumor in the middle portion of the common bile duct. She was suspected of having distal cholangiocarcinoma associated with CBD and underwent pylorus-preserving pancreaticoduodenectomy. Pathological and immunohistological findings led to a final diagnosis of large-cell NEC (pT3aN1M0 pStageIIB). The postoperative course was uneventful, and she was administered cisplatin and irinotecan every 4 weeks (four cycles) as adjuvant chemotherapy. She has remained recurrence-free for 14 months. Conclusion This presentation is rare, and further reports are necessary.
1 January 2026 in Asian Journal of Endoscopic Surgery